MENA Medical Device Market 2026: Size, Investment Trends & Growth Drivers

A Region in the Midst of a Healthcare Investment Boom

The Middle East and North Africa (MENA) medical device market has entered a period of transformative growth. Valued at $24.61 billion in 2025, the market is projected to reach $34.95 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1% according to Fortune Business Insights. This trajectory is fueled by unprecedented government investment, regulatory modernization, and a structural shift toward private-sector healthcare delivery across the Gulf and North Africa.

The signal event was Saudi Arabia's Global Health Exhibition (GHE) 2025 in Riyadh, which generated $35.5 billion in signed deals and partnerships — a six-fold increase in private-sector B2B deal value year-over-year. Over 130,000 attendees, 2,200 exhibiting brands, and 600+ speakers from 25 countries converged under the theme "Invest in Health," reflecting the region's emergence as a global healthcare investment destination.

This article provides a data-driven analysis of the MENA medical device market in 2026, covering market size, investment flows, country-level dynamics, and the structural drivers reshaping the competitive landscape.

Market Size & Growth Projections

Overall MENA Market

The MENA medical device market comprises two overlapping geographies, each measured differently by research firms:

The divergence between the broader ME&A figures ($24.6B) and the narrower Middle East figures ($11–14B) reflects the inclusion of sub-Saharan Africa and different device category definitions. Both trajectories confirm sustained above-global-average growth.

Key Segments Driving Growth

• Ventilators dominated the MEA market with a 28.8% share in 2025, driven by ICU expansion and homecare demand.
• GCC medical consumables are projected to grow from $495 million (2026) to $635 million by 2032.
• Smart medical devices represent a $4.72 billion segment growing at 10.16% CAGR, the fastest sub-category.
• Digital health across MENA is expanding at 19.6% CAGR, encompassing telemedicine platforms, AI diagnostics, remote monitoring, and health information technology.
• Large healthcare facilities (hospitals, specialty clinics, rehabilitation centers) accounted for 45% of device revenue in 2025, driven by ICU expansion, telemedicine-enabled wards, and homecare device programs.

Country-Level Market Analysis

Saudi Arabia: The Dominant Market

Saudi Arabia commands the largest revenue share at 22.5% of the overall MEA medical devices market. Key indicators include:

• SAR 260 billion ($69.3 billion) allocated to health and social development in the 2025 national budget — the second-largest share of government spending.
• The 2026 budget, approved in December 2025, maintains healthcare as a top priority.
• Global Health Exhibition 2025 generated $35.5 billion in deals, including:
  • $8.4 billion for hospital and healthcare infrastructure projects
  • $3.24 billion for venture capital and strategic funds
  • $625 million directed into life sciences
  • SAR 31 billion for hospital infrastructure and healthcare services
  • SAR 12+ billion for venture capital and strategic healthcare funds
  • SAR 2.4+ billion in PIF-backed Lifera partnerships with Sanofi, MSD, Pfizer, BD, Roche, and Siemens Healthineers for localized manufacturing and R&D
• 290 hospitals and 2,300 primary health centres targeted for privatization under Vision 2030.
• Private sector healthcare delivery expected to increase from 40% to 65% by 2030.
• Over 170 healthcare transactions completed between 2021 and April 2025.

Major investment commitments include:

United Arab Emirates: The Innovation Gateway

The UAE medical devices market was valued at approximately $3.18 billion in 2025, projected to reach $4.71 billion by 2032 at a CAGR of 5.8%. Key differentiators:

• 198 healthcare transactions between 2021 and April 2025 — the highest in the GCC.
• Dubai Healthcare City Phase 3: an AED 8 billion ($2.18 billion) expansion including 50 new hospitals, 1,000 clinics, and 20,000 new jobs.
• 100% foreign ownership permitted in both free zones (DHCC) and mainland Dubai since 2021 legal reforms.
• 0% corporate tax for 50 years in DHCC free zone; 0% customs duty on medical equipment imports.
• Fast-track medical licensing within 14 days in DHCC.
• AED 300 billion ($81.6 billion) committed under Operation 300bn to raise the industrial sector's GDP contribution by 2031, with medical devices and equipment designated as a priority sector.
• 7 million medical tourists annually, amplifying demand for specialized devices and diagnostics.

Egypt: The Volume Play

Egypt's medical device market was valued at approximately $4.37 billion in 2024 and is projected to reach $5.58 billion by 2032, making it one of the largest in the MENA region by volume. The Egyptian Drug Authority (EDA) introduced simplified registration measures in February 2026, accepting CE MDR certificates, ISO 13485 certificates, and GMP certificates as documentation routes — accelerating market entry for international manufacturers.

GCC Smaller Markets

Qatar, Kuwait, Bahrain, and Oman collectively represent a growing but fragmented market:

• Kuwait enacted Ministerial Decree 387/2025 establishing three IVD registration pathways (standard, fast-track, abridged).
• Bahrain's NHRA mandated device registration by February 2026.
• Oman's MOH launched Class C&D registration in August 2025, mandatory by July 2026.
• Qatar's MOPH maintains its own registration requirements aligned with Gulf Health Council harmonization efforts.

Investment Trends & Deal Flow

Transaction Volume (2021–2025)

Between 2021 and April 2025, the GCC recorded approximately 400 healthcare transactions, with Saudi Arabia and the UAE accounting for nearly 92% of all deals. The UAE led with 198 transactions, followed by Saudi Arabia with 170. This concentration reflects the two nations' dominance in healthcare infrastructure investment.

Capital Flows by Category

Private Equity and M&A Dynamics

Africa's health-tech sector (a proxy for broader MENA trends) has seen average disclosed deal value rise more than fourfold since 2023, signaling a clear shift toward concentrating capital in higher-quality businesses. In 2025, disclosed deal value had already surpassed the full-year 2024 total by mid-year. Key drivers:

• Investors prioritizing scale-ups over numerous early-stage bets
• Heightened macro risks driving focus on resilient, proven operators
• Capital flowing into capital-intensive segments: infrastructure, pharma, MedTech, and hospital networks
• Increased participation from institutional and strategic investors pushing up ticket sizes

Medical Device Contract Manufacturing

The global medical device contract manufacturing market was valued at $95.81 billion in 2025, estimated to reach $171.03 billion by 2031 at a CAGR of 10.14%. For MENA specifically, the region is "gradually scaling single-use device production to serve expanding local healthcare demand," as OEMs diversify away from single-site manufacturing vulnerabilities exposed during the pandemic.

Structural Growth Drivers

1. Government-Led Healthcare Transformation

The two largest national programs are reshaping demand:

• Saudi Vision 2030 / HSTP: Privatizing 290 hospitals, increasing private sector share to 65%, establishing health clusters, and expanding the Seha Virtual Hospital (now the world's largest).
• UAE Vision 2031 / Operation 300bn: Targeting AED 300 billion in industrial GDP contribution, with medical devices as a priority sector. The UAE aims to be among the world's top 10 healthcare systems.

2. Regulatory Modernization

Across MENA, regulators are establishing clearer, more predictable pathways:

• UAE: EDE consolidation of 44 regulatory services from MOHAP (January 2025), new anti-monopoly distribution requirements (February 2026).
• Saudi Arabia: SFDA MDS-G27 digital health guidance (August 2025), MDS-G11 manufacturing paths Version 2.0 (July 2025), LCGPA increasing minimum local content requirements.
• Egypt: EDA simplified registration (February 2026), EU MDR-aligned classification.
• Kuwait: Decree 387/2025 for IVD registration pathways.
• Oman: MOH Class C&D registration launch (August 2025).

3. Demographic and Epidemiological Demand

• Chronic diseases drive 70% of UAE healthcare spending, creating sustained demand for oncology, cardiology, neurology, and diabetes care devices.
• By 2050, residents aged 60+ are expected to account for 29% of the UAE population (up from under 10% today), driving long-term demand for specialist and eldercare devices.
• Saudi Arabia's population is projected to reach 39.5 million by 2030, with high rates of heart disease, stroke, diabetes, and respiratory disease.

4. Localization Requirements

Both Saudi Arabia and the UAE are pushing for local manufacturing:

• Saudi Arabia's LCGPA: "Made in Saudi" program requires 40% added local value for product approval in government tenders. The LCGPA announced increases in minimum local content percentages in February 2026, effective August 2028.
• NIDLP targets: Localize 40% of pharmaceutical industry market value; raise local content in oil and gas to 75%.
• UAE's Operation 300bn: Medical devices and equipment designated as a priority sector for domestic production.
• SFDA MDS-G11 Version 2.0 (effective July 2025): Three defined manufacturing paths — full local manufacturing, partial local manufacturing (assembly), and a third pathway — providing regulatory clarity for localization strategies.

5. Digital Health Adoption

The convergence of digital health and medical devices is accelerating across MENA:

• Saudi Arabia: SFDA Digital Health Platform workshops at GHE 2025, Seha Virtual Hospital (world's largest), AI-powered diagnostic tools in clinical deployment.
• UAE: Abu Dhabi DOH Responsible AI Standard (October 2025), EDE registration frameworks for AI-enabled devices, UAE National AI Strategy 2031.
• Turkey: Regulation on Provision of Remote Health Services (2022), TITCK medical device classification for software, proposed AI and Digital Health Applications Regulation.

Market Entry Implications

For medical device manufacturers considering MENA market entry or expansion, several strategic considerations emerge:

1. Saudi Arabia and the UAE should be primary targets: Together they account for 92% of GCC healthcare transactions and host the region's most developed regulatory infrastructure.

2. Localization is becoming a prerequisite, not an option: LCGPA requirements in Saudi Arabia and Operation 300bn incentives in the UAE reward local manufacturing, assembly, and technology transfer. Companies without a localization strategy will face increasing competitive disadvantage in government procurement.

3. Digital health is the fastest-growing segment: At 19.6% CAGR, digital health represents the region's highest-growth opportunity. Manufacturers with AI-enabled devices, telemedicine solutions, and connected devices are particularly well-positioned.

4. Regulatory pathways are stabilizing: The EDE in the UAE, SFDA in Saudi Arabia, and EDA in Egypt have all introduced clearer, more predictable registration processes in 2025–2026, reducing market entry timelines.

5. Egypt offers volume at lower regulatory cost: The EDA's simplified registration (February 2026) and EU MDR alignment make Egypt an increasingly accessible market, particularly for high-volume device categories.

Outlook: 2026–2032

The MENA medical device market is in the early innings of a multi-decade growth cycle. The combination of Vision 2030 (Saudi Arabia), Vision 2031 (UAE), regulatory modernization across the region, and demographic tailwinds creates a secular demand environment. The $35.5 billion in deals at GHE 2025 — six times the prior year — confirms that capital is flowing at an accelerating pace.

For medical device companies, the question is no longer whether to enter MENA, but how quickly and through what structure. The data suggests that companies establishing local manufacturing, digital health capabilities, and regulatory partnerships in 2026–2027 will capture disproportionate market share as the region's healthcare transformation moves from design to execution.